Chun-wa Chung

Chun-wa Chung is the Executive Director and Head of Structural and Biophysical Sciences at GlaxoSmithKline (GSK), where she leads a global, multi-disciplinary department providing molecular insights into drug discovery programmes that span all GSK modalities, including small molecules, oligonucleotides, biopharmaceuticals, and vaccines. Her teams, based in Stevenage and Philadelphia, utilise state-of-the-art crystallography, electron microscopy, and biophysical approaches across the breadth of drug discovery activities—from orthogonal hit triage and mode-of-action analysis to understanding epitope diversity and developing strategies for new modalities such as PROTACs, molecular glues, and ADCs.

With over 25 years of industrial pharmaceutical experience, Chun-wa’s career started with a BA and PhD from the University of Cambridge where she focused integrating computational and experimental innovations in NMR. She has since led and supported many early project teams across multiple therapeutic areas, contributing to the advancement of several clinical candidates.  Notably, her team was instrumental in uncovering the mechanistic and structural basis of Blujepa (gepotidacin), GSK’s first-in-class oral antibiotic for UTIs, providing an important new option against drug-resistant infections.